Advances in sarcoma genomics and new therapeutic targets

BS Taylor, J Barretina, RG Maki, CR Antonescu… - Nature Reviews …, 2011 - nature.com
Increasingly, human mesenchymal malignancies are being classified by the abnormalities
that drive their pathogenesis. Although many of these aberrations are highly prevalent within …

Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation

S Ricci, RL Stone, AN Fader - Gynecologic oncology, 2017 - Elsevier
Leiomyosarcoma, a rare tumor subtype, accounts for 1% of all uterine malignancies, but
contributes to a significant proportion of uterine cancer deaths. Surgery is considered the …

B cells are associated with survival and immunotherapy response in sarcoma

F Petitprez, A de Reyniès, EZ Keung, TWW Chen… - Nature, 2020 - nature.com
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …

Comprehensive and integrated genomic characterization of adult soft tissue sarcomas

AJ Lazar, MD McLellan, MH Bailey, CA Miller… - Cell, 2017 - discovery.ucl.ac.uk
Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic
diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue …

Comprehensive and integrated genomic characterization of adult soft tissue sarcomas

A Abeshouse, C Adebamowo, SN Adebamowo… - Cell, 2017 - cell.com
Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic
diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue …

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

L Paoluzzi, A Cacavio, M Ghesani… - Clinical sarcoma …, 2016 - Springer
Background Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted
antibodies has recently emerged as an effective anticancer strategy in multiple …

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: a propensity score matching …

L D'Ambrosio, N Touati, JY Blay, G Grignani… - Cancer, 2020 - Wiley Online Library
Background The optimal treatment for advanced leiomyosarcoma is still debated. Given
histotype‐specific prospective controlled data lacking, this study retrospectively evaluated …

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

B Edris, K Weiskopf, AK Volkmer… - Proceedings of the …, 2012 - National Acad Sciences
Antibodies against CD47, which block tumor cell CD47 interactions with macrophage signal
regulatory protein-α, have been shown to decrease tumor size in hematological and …

TP53 in bone and soft tissue sarcomas

E Thoenen, A Curl, T Iwakuma - Pharmacology & therapeutics, 2019 - Elsevier
Genomic and functional study of existing and emerging sarcoma targets, such as fusion
proteins, chromosomal aberrations, reduced tumor suppressor activity, and oncogenic …

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

HJ Lim, P Crowe, JL Yang - Journal of cancer research and clinical …, 2015 - Springer
Purpose PTEN is an essential tumour suppressor gene which encodes a phosphatase
protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this …